// App-Quantinova.ai

THU0095 : IMPACT OF BASELINE EROSION SCORE ON RESPONSE TO TREATMENT AND FUTURE RADIOLOGICAL DAMAGE IN AVERT-2, A RANDOMISED PHASE IIIB STUDY OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY–POSITIVE (ACPA+) PATIENTS WITH EARLY RA

Researchers

Presenter

  • C. Pachai

Principal Investigators

  • S. Connolly

  • J. Landis

  • Y. Tanaka

  • V. Bykerk

  • T. Huizinga

  • G. Citera

  • C. Bingham

  • R. Wong

  • K. H. G. Huang

  • S. Du

  • W. Hayes

  • C. Wu

  • R. Fleischmann

  • P. Emery

Medical Centers

  • Bristol-Myers Squibb Company, Lawrencville, NJ, United States of America

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Leiden University Medical Centre, Leiden, Netherlands

  • Instituto de Rehabilitacion Psicofisica, Buenos Aires, Buenos Aires, Argentina

  • The Johns Hopkins University, Baltimore, United States of America

  • LIRMM, University of Leeds, NIHR BRC LTHT, Leeds, United Kingdom

Locations

  • United States

  • Japan

  • Netherlands

  • Argentina

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02504268

Sponsors

  • Asahi Kasei

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved